Gelesis Holdings (GLSHQ)
OTHER OTC:GLSHQ
GLSHQ Stock Chart & Stats
$0.02
<$0.01(9900.00%)
At close: 4:00 PM EST
$0.02
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.02
Previous CloseN/A
Volume50.00K
Average Volume (3M)0.00
Market Cap
$73.00
Enterprise Value$66.48M
Total Cash (Recent Filing)$7.91M
Total Debt (Recent Filing)$61.88M
Price to Earnings (P/E)―
Beta-143.99
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding73,335,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.81
Price to Sales (P/S)0.79
P/FCF Ratio-0.23
Enterprise Value/Market Cap910.71K
Enterprise Value/Revenue5.48
Enterprise Value/Gross Profit-8.92
Enterprise Value/Ebitda-1.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GLSHQ FAQ
What was Gelesis Holdings’s price range in the past 12 months?
Gelesis Holdings lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is Gelesis Holdings’s market cap?
Gelesis Holdings’s market cap is $73.00.
When is Gelesis Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Gelesis Holdings’s earnings last quarter?
Currently, no data Available
Is Gelesis Holdings overvalued?
According to Wall Street analysts Gelesis Holdings’s price is currently Overvalued.
Does Gelesis Holdings pay dividends?
Gelesis Holdings does not currently pay dividends.
What is Gelesis Holdings’s EPS estimate?
Gelesis Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gelesis Holdings have?
Gelesis Holdings has 73,335,110 shares outstanding.
What happened to Gelesis Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Gelesis Holdings?
Currently, no hedge funds are holding shares in GLSHQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gelesis Holdings
Gelesis Holdings, Inc. operated as a commercial-stage biotherapeutics company, concentrating on the development of biomimetic solutions. Its core mission revolved around addressing the root causes of obesity and various chronic gastrointestinal ailments. Among its offerings was PLENITY, an orally administered, non-stimulant, and non-systemic product designed to assist with weight management. The company's pipeline also included several other promising developments: GS200, targeting weight reduction for individuals with prediabetes and type 2 diabetes; and GS500, intended for the treatment of functional constipation. Furthermore, Gelesis had a pre-clinical stage product, GS300, in development for conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Founded in Boston, Massachusetts, in 2006, the company established its headquarters there. Regrettably, on October 30, 2023, Gelesis Holdings, Inc., alongside its affiliates, formally initiated voluntary Chapter 7 liquidation proceedings in the U.S. Bankruptcy Court for the District of Delaware.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
20.44% Other Institutional Investors
79.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---